These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Antidepressant-like effect of the hydroethanolic leaf extract of Alchornea cordifolia (Schumach. & Thonn.) Mull. Arg. (Euphorbiaceae) in mice: involvement of monoaminergic system. Ishola IO; Agbaje EO; Akinleye MO; Ibeh CO; Adeyemi OO J Ethnopharmacol; 2014 Dec; 158 Pt A():364-72. PubMed ID: 25448506 [TBL] [Abstract][Full Text] [Related]
23. Uliginosin B, a phloroglucinol derivative from Hypericum polyanthemum: a promising new molecular pattern for the development of antidepressant drugs. Stein AC; Viana AF; Müller LG; Nunes JM; Stolz ED; Do Rego JC; Costentin J; von Poser GL; Rates SM Behav Brain Res; 2012 Mar; 228(1):66-73. PubMed ID: 22155486 [TBL] [Abstract][Full Text] [Related]
24. The involvement of serotonergic system in the antidepressant effect of zinc in the forced swim test. Szewczyk B; Poleszak E; Wlaź P; Wróbel A; Blicharska E; Cichy A; Dybała M; Siwek A; Pomierny-Chamioło L; Piotrowska A; Brański P; Pilc A; Nowak G Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):323-9. PubMed ID: 19150479 [TBL] [Abstract][Full Text] [Related]
25. Antidepressant-like activity of a new piperazine derivative of xanthone in the forced swim test in mice: The involvement of serotonergic system. Pytka K; Rapacz A; Zygmunt M; Olczyk A; Waszkielewicz A; Sapa J; Filipek B Pharmacol Rep; 2015 Feb; 67(1):160-5. PubMed ID: 25560591 [TBL] [Abstract][Full Text] [Related]
26. Future antidepressants: what is in the pipeline and what is missing? Bosker FJ; Westerink BH; Cremers TI; Gerrits M; van der Hart MG; Kuipers SD; van der Pompe G; ter Horst GJ; den Boer JA; Korf J CNS Drugs; 2004; 18(11):705-32. PubMed ID: 15330686 [TBL] [Abstract][Full Text] [Related]
28. Monoamine involvement in the antidepressant-like effect induced by P2 blockade. Diniz CRAF; Rodrigues M; Casarotto PC; Pereira VS; Crestani CC; Joca SRL Brain Res; 2017 Dec; 1676():19-27. PubMed ID: 28916441 [TBL] [Abstract][Full Text] [Related]
29. Antidepressant properties of substance P antagonists: relationship to monoaminergic mechanisms? Adell A Curr Drug Targets CNS Neurol Disord; 2004 Apr; 3(2):113-21. PubMed ID: 15078186 [TBL] [Abstract][Full Text] [Related]
30. The monoaminergic tripartite synapse: a putative target for currently available antidepressant drugs. Quesseveur G; Gardier AM; Guiard BP Curr Drug Targets; 2013 Oct; 14(11):1277-94. PubMed ID: 24020973 [TBL] [Abstract][Full Text] [Related]
32. New approaches to developing antidepressants by enhancing monoaminergic neurotransmission. Bymaster FP; McNamara RK; Tran PV Expert Opin Investig Drugs; 2003 Apr; 12(4):531-43. PubMed ID: 12665410 [TBL] [Abstract][Full Text] [Related]
33. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. López-Muñoz F; Alamo C Curr Pharm Des; 2009; 15(14):1563-86. PubMed ID: 19442174 [TBL] [Abstract][Full Text] [Related]